<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In this review we discuss the position of electrical neuromodulation as a safe and reversible adjuvant therapy for treatment of patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">cardiac diseases</z:e> who have become refractory to conventional strategies </plain></SENT>
<SENT sid="1" pm="."><plain>In patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> refractory <z:mp ids='MP_0006112'>angina</z:mp>, electrical neuromodulation, independent of the applied modality, has shown to reduce complaints of <z:mp ids='MP_0006112'>angina</z:mp>, to enhance exercise capacity, to improve quality of life and to employ anti-ischaemic effects </plain></SENT>
<SENT sid="2" pm="."><plain>To date, electrical neuromodulation seems to be one of the best adjuvant therapies for these patients </plain></SENT>
<SENT sid="3" pm="."><plain>In addition, neuromodulation in the treatment of <z:hpo ids='HP_0001635'>heart failure</z:hpo> and resistant <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> is the subject of several ongoing studies </plain></SENT>
</text></document>